Ropes & Gray represented Vir Biotechnology in the transaction. Vir Biotechnology (Nasdaq: VIR) announced it has entered into an exclusive worldwide license agreement with Sanofi for...
Vir Biotechnology’s License Agreement with Sanofi
Amylyx Pharmaceuticals’ Acquisition of Phase 3-Ready Asset from Eiger BioPharmaceuticals
Ropes & Gray represented Amylyx Pharmaceuticals in the transaction and Sidley Austin represented Eiger BioPharmaceuticals. Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx) announced the acquisition of a...
Takeda Pharmaceuticals’ $1.2 Billion License Agreement with Degron Therapeutics
Ropes & Gray advised Takeda Pharmaceuticals on the deal. Takeda Pharmaceuticals announced it has entered into a collaboration and exclusive license agreement with Degron Therapeutics (“Degron”)...
FogPharma’s Collaboration with ARTBIO
Ropes & Gray advised FogPharma on the transaction. FogPharma announced a collaboration with ARTBIO Inc. to co-develop new radiopharmaceuticals that would use FogPharma’s Helicon peptides platform,...
Gilgamesh Pharmaceuticals’ Collaboration with AbbVie
Ropes & Gray represented Gilgamesh Pharmaceuticals in a transaction. Gilgamesh Pharmaceuticals announced it has entered into a collaboration and option-to-license agreement with AbbVie (NYSE: ABBV) to...
Novavax’s $1.4 Billion Licensing Agreement with Sanofi
Ropes & Gray represented Novavax Inc. in the transaction. Novavax Inc.(Nasdaq: NVAX) announced it has entered into a co-exclusive licensing agreement with French pharmaceutical company Sanofi...
Novo Nordisk’s Collaboration with Flagship Pioneering and Metaphone Biotechnologies
Ropes & Gray advised Novo Nordisk on the transaction. Novo Nordisk announced it has entered into a research collaboration agreement with Flagship Pioneering and Metaphone Biotechnologies,...
Gilead Sciences’ $647.5 Million License Agreement with Xilio Therapeutics
Ropes & Gray and Wilmer Cutler Pickering Hale and Dorr represented Xilio Therapeutics, Inc. in the deal. Xilio Therapeutics, Inc.(Nasdaq: XLO), announced it has entered into...
Allorion Therapeutics’ Licensing Agreement with Avenzo Therapeutics
Ropes & Gray advised Allorion Therapeutics on the transaction. Allorion Therapeutics (Allorion) announced it entered into a global licensing agreement with Avenzo Therapeutics Inc. (Avenzo) to develop and...
MOMA Therapeutics’ Collaboration and Licensing Agreement with Roche
Ropes & Gray advised MOMA Therapeutics on the deal. MOMA Therapeutics announced a collaboration and licensing agreement with Swiss pharmaceutical leader Roche (SIX: RO, ROG; OTCQX: RHHBY)....
Accutar Biotechnology’s Collaboration with Evommune
Ropes & Gray advised Accutar Biotechnology on the transaction. Accutar Biotechnology announced a partnership with Evommune focused on the discovery of novel small molecule drug candidates in...
Acumen Pharmaceuticals’ Global Collaboration and License Agreement with Halozyme Therapeutics
Ropes & Gray advised Acumen Pharmaceuticals on the transaction. Acumen Pharmaceuticals (Nasdaq:ABOS) (“Acumen”) announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics (Nasdaq:HALO) (“Halozyme”). Acumen will...